US 10,376,516 B2
Methods and devices for renal nerve blocking
Mark Gelfand, New York, NY (US); and Howard R. Levin, Teaneck, NJ (US)
Assigned to Medtronic Ardian Luxembourg S.a.r.l., Luxembourg (LU)
Filed by Medtronic Ardian Luxembourg S.a.r.l., Luxembourg (LU)
Filed on Apr. 24, 2018, as Appl. No. 15/960,596.
Application 15/960,596 is a continuation of application No. 14/878,371, filed on Oct. 8, 2015, granted, now 9,968,611.
Application 14/878,371 is a continuation of application No. 14/221,536, filed on Mar. 21, 2014, granted, now 9,192,715, issued on Nov. 24, 2015.
Application 14/221,536 is a continuation of application No. 11/133,925, filed on May 20, 2005, granted, now 8,771,252, issued on Jul. 8, 2014.
Application 11/133,925 is a continuation of application No. 10/900,199, filed on Jul. 28, 2004, granted, now 6,978,174, issued on Dec. 20, 2005.
Application 10/900,199 is a continuation in part of application No. 10/408,665, filed on Apr. 8, 2003, granted, now 7,162,303, issued on Jan. 9, 2007.
Claims priority of provisional application 60/370,190, filed on Apr. 8, 2002.
Claims priority of provisional application 60/415,575, filed on Oct. 3, 2002.
Claims priority of provisional application 60/442,970, filed on Jan. 29, 2003.
Prior Publication US 2018/0303839 A1, Oct. 25, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/32 (2006.01); A61N 1/36 (2006.01); A61N 1/05 (2006.01); A61N 1/362 (2006.01); A61K 31/529 (2006.01); A61M 5/142 (2006.01); A61M 5/172 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61L 29/14 (2006.01); A61M 5/145 (2006.01); A61K 31/135 (2006.01); A61K 31/52 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/529 (2013.01) [A61K 9/0004 (2013.01); A61K 9/0012 (2013.01); A61K 9/7007 (2013.01); A61K 31/135 (2013.01); A61K 31/52 (2013.01); A61K 45/06 (2013.01); A61L 29/146 (2013.01); A61M 5/145 (2013.01); A61M 5/14276 (2013.01); A61M 5/1723 (2013.01); A61N 1/326 (2013.01); A61N 1/36114 (2013.01); A61M 2005/14513 (2013.01); A61M 2205/05 (2013.01); A61M 2205/50 (2013.01); A61M 2210/1082 (2013.01); A61N 1/0551 (2013.01); A61N 1/36007 (2013.01); A61N 1/3627 (2013.01); A61N 1/36117 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method, comprising:
delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient via a drug delivery catheter; and
at least partially blocking neural activity along the renal nerve to and from a kidney of the patient with the neuromodulatory agent,
wherein at least partially blocking neural activity along the renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.